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Abstract
Fibrosis is a significant health problem associated with a chronic inflammatory reaction. The precise mechanisms involved in
the fibrotic process are still poorly understood. However, given that inflammation is a major causative factor,
immunomodulation is a possible therapeutic approach to reduce fibrosis. The vitamin D receptor (VDR) that is present
in all hematopoietic cells has been associated with immunomodulation. We investigated whether the intraperitoneal
administration of paricalcitol, a specific activator of the VDR, modulates peritoneal dialysis fluid (PDF)-induced peritoneal
fibrosis. We characterized the inflammatory process in the peritoneal cavity of mice treated or not treated with paricalcitol
and analyzed the ensuing fibrosis. The treatment reduced peritoneal IL-17 levels, which strongly correlated with a
significantly lower peritoneal fibrotic response. In vitro studies demonstrate that both CD4+ and CD8+ regulatory T cells
appear to impact the regulation of IL-17. Paricalcitol treatment resulted in a significantly increased frequency of CD8+ T cells
showing a regulatory phenotype. The frequency of CD4+ Tregs tends to be increased, but it did not achieve statistical
significance. However, paricalcitol treatment increased the number of CD4+ and CD8+ Treg cells in vivo. In conclusion, the
activation of immunological regulatory mechanisms by VDR signaling could prevent or reduce fibrosis, as shown in
peritoneal fibrosis induced by PDF exposure in mice.
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Introduction
Tissue fibrosis is the consequence of abnormal healing processes
that are typically associated with chronic inflammation, and is an
important cause of morbidity and mortality. The molecular and
cellular mechanisms that contribute to the development of
fibroproliferative diseases are still poorly understood, hindering
the development of efficient therapies. Understanding the specific
mechanisms involved could contribute to the development of
therapeutic procedures.
Peritoneal dialysis (PD) is a renal replacement therapy for
patients with end-stage renal disease (ESRD). This therapy uses
the peritoneum as a semi-permeable membrane, exposing it to a
bio-incompatible, glucose-containing hyperosmotic solution
known as peritoneal dialysis fluid (PDF). When chronically
exposed to PDF, patients develop peritoneal fibrosis and
ultrafiltration failure, which compromises treatment efficacy and
patient outcomes [1]. The mesothelial cell monolayer is the first
line of contact between the PDF and the body, and could trigger a
peritoneal aseptic inflammatory process. The exposure of meso-
thelial cells to glucose degradation products (GDPs), Amadori
adducts and advanced glycation end products (AGEs) stimulated
NF-kB-mediated transcription and the secretion of cytokines and
chemokines in vitro [2,3,4]. PD results in increased serum
concentrations of IL-6, TNF-a, VEGF and C-reactive proteins
in patients, which suggests that PD leads to increased systemic
inflammation [5,6]. Using a mouse model of chronic peritoneal
exposure to PDF, we had already demonstrated that PDF induces
peritoneal membrane inflammation and fibrosis [7]. The use of an
anti-inflammatory drug (a Cox-2 inhibitor) reduced peritoneal
inflammation and fibrosis [8]. This result confirms the role of
inflammation in peritoneal fibrosis. However, the cardiovascular
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effects of this drug family preclude its use in patients undergoing
PD.
In addition to its classic metabolic action, vitamin D has an
immunomodulatory function. The vitamin D receptor (VDR) is a
nuclear hormone receptor expressed in B, T, macrophages and
dendritic cells, and it regulates their proliferation and function [9].
Vitamin D can prevent or ameliorate inflammatory disease in
animal autoimmune disease models [10] and in patients [11]. The
mechanism by which vitamin D regulates inflammatory response
appears to be dependent on the activation of regulatory CD4+ T
cells [12]. These regulatory CD4+ T cells control IL-17 and IFN-c
secretion [13,14,15]. Because inflammation plays an important
role in peritoneal fibrosis, vitamin D receptor (VDR) signaling
might have a beneficial impact on PDF-induced peritoneal
fibrosis. Paricalcitol is a selective VDR activator used to treat
secondary hyperparathyroidism, a disorder often seen in patients
with chronic renal failure. As a VDR activator, paricalcitol has
shown anti-inflammatory activity [16]. Therefore, given its various
therapeutic targets, paricalcitol could represent a very interesting
treatment for patients undergoing PD. To address the impact of
VDR signaling on peritoneal fibrosis, paricalcitol was added to a
commercial PDF, and its effect on PDF-induced peritoneal
inflammation and fibrosis was addressed in a mouse model of
peritoneal dialysis. The results demonstrate that paricalcitol
prevents peritoneal membrane deterioration, reducing fibrosis
and ultrafiltration failure. The mechanism of protection appears to
be dependent on the increased frequency of regulatory T cells and
the reduction in IL-17 production in the peritoneal cavity.
Materials and Methods
Animals and surgery
The experimental procedure was approved by the ethics
committee for animal welfare of La Paz University Hospital
(CEBA 06-2009). Female C57BL/6 mice, from 12–14 weeks of
age, were purchased from Charles River (Barcelona, Spain) and
maintained in conventional conditions in our animal facilities.
Catheter implantation was performed as previously described [8].
The state of the animals’ health was checked daily by a
veterinarian, and mice presenting any sign of illness were excluded
from the experiment. Only 3 mice were excluded from the
experiment. The cause of exclusion was an infection at the site of
the subcutaneous pump.
We used 3 groups of mice in these experiments. These groups
were repeated in duplicate to analyze both the ultrafiltration
capacity of the peritoneum and the production of cytokines and
chemokines. These two measurements were not performed
together because they required technical differences during
euthanasia. Thereby, the experiments were performed in dupli-
cate, and were repeated at least twice. The control group had a
catheter and received no PDF (n = 6). This group was used to
demonstrate that a catheter alone does not affect the peritoneal
membrane. The PDF group received an instillation of 2 ml of
staysafe (4.25% glucose) PDF (Fresenius Medical Care, Germany)
daily through the catheter (n = 10). The paricalcitol group received
2 ml of staysafe (4.25% glucose) supplemented with paricalcitol
daily (n = 11). The mice were treated for 30 days. At the end of the
experiment, the mice were visually checked for the presence of
peritoneal infection (signs of pus at the peritoneal cavity), and
peritoneal washing fluid from the 3 mouse groups was seeded in
agar plates for bacterial culture; no bacterial infection was
detected. To study the mechanisms involved in paricalcitol
peritoneal protection, we performed only the comparison between
the PDF and the paricalcitol groups.
The experimental procedure was performed according to NIH
guidelines for the care and use of laboratory animals and was
approved by the institutional ethics committee.
Paricalcitol treatment
Paricalcitol dissolved in PDF was instilled daily into the mouse
peritoneal cavity for 30 days, at a dosage of 0.3 mg/kg/week
(0.86 ng/mouse/day). The dose used in mice is low considering
the translation to humans based on body surface area [17], which
would mean that human patients should receive about 0.024 mg/
kg/week, whereas they normally receive 0.117 mg/kg/week.
Histological analyses and immunofluorescence
Parietal peritoneal biopsies were collected from the opposite side
of the catheter installation. Part of the biopsies were fixed in
Bouin’s solution, embedded in paraffin, cut into 5 mm sections and
stained with Masson’s trichrome. The peritoneal membrane
thickness was determined using a microscope (Leica CTR6000,
with a Leica Microsystems LAS-AF6000). Microphotographs were
obtained using an Olympus BX41 clinical microscope and an
Olympus DP20 digital camera using cell acquisition software.
The peritoneal thickness of each mouse was calculated by the
median of measurement taken every 50 mm from one extreme to
the other of the biopsy. The result was used to calculate the group
thickness.
For the immunofluorescence analysis, other biopsies were
frozen in optimal cutting temperature (OCT) compound and cut
into 5 mm sections. To identify the mesothelial cells, a mouse anti-
cytokeratin 8/18 (clone 5D3 Novocastra, Newcastle, UK)
antibody was used, which was stained with anti-IgG1 specific
Zenon Fab fragments (Invitrogen, Eugene, OR, USA) according
to the manufacturer’s instructions. The blood vessels were stained
with anti-CD31 and Zenon Fab. The CD45+ cells were identified
using a rat anti-mouse CD45 (BD Bioscience) and were stained
with goat anti-rat antibodies. To stain CD4+ and CD8+ cells, the
same antibodies used in flow cytometry were employed. The
nuclei were stained with DAPI. The micrography was performed
with a fluorescence microscope (Leica CTR6000, Leica Micro-
systems Heidelberg, Germany, with LAS-AF6000 software) or
with a confocal microscope (Leica TCS SPE with LAS-AF
software, version 2.0.1 build 2043).
Net ultrafiltration
On the final day of the experiment, the mice were euthanized
40 minutes after receiving 2 ml of PDF, and the total peritoneal
volume was drained and measured.
Chemokine and cytokine detection
To determine the peritoneal production of cytokines and
chemokines, the peritoneal cavity was washed in this case with
2 ml of saline immediately after the mice were euthanized. The
molecule concentration is thereby not affected by the differences in
ultrafiltration. The solution was centrifuged, and the supernatant
was separated into small aliquots and stored at -80uC. The
peritoneal chemokines and cytokines were determined using the
FlowCytomix technique (Bender MedSystems GmbH).
Flow cytometry analyses
The peritoneal cells were analyzed by flow cytometry using the
following antibodies purchased from BD Biosciences (San Diego,
CA, USA): anti-mouse CD4 PE, anti-mouse CD3e biotin, anti-
mouse CD8a Alexa Fluor 488-labeled and anti-Foxp3 Alexa 647.
FoxP3 stainning was performed according to the manufacturer’s
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Figure 1. Paricalcitol reduced peritoneal membrane fibrosis, inflammation and ultrafiltration failure in mice exposed to PDF. A)
Paraffin sections of the peritoneal membrane from the 3 groups were stained with Masson’s trichrome. B) Thickening of the peritoneal membrane
was determined by morphometric analysis. C) Peritoneal permeability was determined by net ultrafiltration. D) The presence of inflammatory and
mesothelial cells was determined by the expression of CD45 (green) and cytokeratin (red), respectively, in frozen sections of peritoneal membrane
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recommendations in the kit ‘‘Mouse FoxP3 Buffer set’’ (BD
Pharmingen).
The biotin-conjugated anti-CTLA4 and PE-Cy7-conjugated
streptavidin were acquired from eBioscience (San Diego, USA).
The flow cytometry analysis was conducted on a FACSCalibur
flow cytometer (BD Biosciences) using Cell Quest Pro software.
Determination of IL-17 producing cells
Peritoneal cells from the PDF-treated mice were enriched in T
cells by negative selection using magnetic beads coated with
monoclonal antibodies against unrelated populations. The elim-
ination of bead linked cells was performed in an autoMACS cell
separator (Miltenyi Biotec) according to the manufacturer’s
instructions. These cells enriched in T lymphocytes were used as
the ‘‘effector T cell’’ population. Meanwhile, cells from the PDF or
paricalcitol-treated groups were divided and enriched in CD4+ or
CD8+ T cells through negative selection of irrelevant cells to
analyze their regulatory capacity. These CD4+ and CD8+
enriched T cell populations were stained with PKH67 (PKH67
green fluorescent linker; Sigma Aldrich) and cocultured with the
enriched T cell population from the PDF-treated mice, at a ratio
1:1(756103 cells of each population). A negative control without
the CD4+ or CD8+ enriched T cell populations was also analyzed.
The cells were cultured for 2 days in a 96-well plate pre-coated
for 24 h at 4uC with anti-CD3 antibody (purified hamster anti-
mouse CD3e; BD Biosciences) and activated with anti-CD28
(2 mg/ml) antibody (purified hamster anti-mouse CD28; BD
Biosciences). On the final day, the cells were exposed to brefeldin
A (2.5 mg/mL) for 12 h, and the expression of intracellular IL-17
was then analyzed by flow cytometry. Finally, the frequency of the
IL-17+ CD4+ T cells from the PKH67 ———negative population was
determined.
Statistical analysis
The data were analyzed using GraphPad Prism (version 4) (La
Jolla, CA, USA) software for Macintosh, and the results were
presented in box plot graphics. The bottom and top of the box
represent the first and third quartiles, and the median is
represented by the band inside the box. The ends of the whiskers
represent minimum and maximum values. Comparisons between
the control and the paricalcitol groups were performed using the
nonparametric Mann-Whitney U test. A value of P,.05 was
considered statistically significant. All the experiments were
repeated at least twice. The correlation analysis was performed
using Spearman’s nonparametric test.
Results
Paricalcitol treatment ameliorated peritoneal
inflammation and fibrosis
PDF treatment was shown to induce peritoneal fibrosis in mice.
To evaluate the effect of VDR signaling on peritoneal fibrosis,
representative of each group. A green arrow indicates hematopoietic cells. A red arrow indicates mesothelial cells. E) The angiogenesis was
determined by the expression of CD31 (green). Cytokeratin-positive cells are stained in red. The color balance was equally adjusted in
immunofluorescence using Photoshop V10 for Mac (Abobe Systems Incorporated, US). n$5 in each group. Statistical significance was determined
using the Mann-Whitney test. *P,.05; ***P,.001.
doi:10.1371/journal.pone.0108477.g001
Figure 2. Paricalcitol changed the peritoneal T cell population in mice instilled with PDF. A) The paricalcitol group tends to increase the
number of nucleated cells at the peritoneal cavity compared with the PDF group. B) The number of B cells was similar in the PDF and paricalcitol
groups. C) There is no significant difference between the number of macrophages in the PDF and paricalcitol groups. D) Paricalcitol increased the
numbers of CD4+ T cells compared with the PDF group. E) The treatment with paricalcitol increased CD8+ T cells in the peritoneal cavity. Statistical
significance was determined using the Mann-Whitney test. ***P,.001; n$5 in each group.
doi:10.1371/journal.pone.0108477.g002
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intraperitoneal paricalcitol was administered daily with PDF in an
independent group of mice, and the thickness of peritoneal
membrane was evaluated as a measure of peritoneal fibrosis.
Masson’s trichrome staining of the peritoneal biopsies revealed
that the paricalcitol group had less matrix deposition and cell
infiltration in the peritoneal membrane than the PDF group
(Figure 1A). This was confirmed by a morphometric analysis,
which showed thicker peritoneal membranes in the PDF-treated
group as compared with the paricalcitol-treated group (Figure 1B).
Increased thickness was the consequence of cellular and matrix
deposition over the peritoneal membrane.
A functional analysis of the peritoneal membranes revealed that
the paricalcitol group had better ultrafiltration than the PDF
group (Figure 1C, P,.05). This result might be the consequence
of paricalcitol’s effect on inflammation and angiogenesis. In the
peritoneal membranes of the PDF group, CD45+ cells were found
on both sides of the mesothelial cell layer, which was not well
preserved. The mesothelial cells of the paricalcitol-treated mice
were better preserved than in the PDF group, and CD45+ cells
were present in lower numbers and located primarily in the sub-
mesothelial space (Figure 1D).
One of the key events in tissue regeneration is angiogenesis at
the fibrotic area generating granulose tissue. In PD-treated
patients, this is related to ultrafiltration failure. This effect was
also found in PDF-treated mice, which presented blood vessels
embedded in the inflammatory zone. In addition, these mice had
Figure 3. Paricalcitol’s enhancement of T cell numbers is inversely correlated with peritoneal thickness. The increased levels of CD4+ (A)
and CD8+ (B) T cells are strongly correlated with lower peritoneal fibrosis. n$5 in each group. Statistical significance was determined using the Mann-
Whitney test. A correlation analysis was performed using Spearman’s nonparametric test.
doi:10.1371/journal.pone.0108477.g003
Figure 4. Paricalcitol induced the recruitment of regulatory CD8+ T cells into the peritoneal cavity. Paricalcitol (dashed box) tended to
increase the frequency of CD4+ T cells expressing Foxp-3 (A), but not CTLA-4 (B) or membrane TGF-b (C). Paricalcitol increased the frequency of CD8+
T cells expressing Foxp-3 (A), CTLA-4 (B) and membrane TGF-b (C) compared with the PDF-group (white box). n$9 in each group. Paricalcitol treated
group had higher number of CD4+ CD8+ T cells expressing Foxp-3 than PDF group (D). Statistical significance was determined using the Mann-
Whitney test. *P,.05; **P,.01; ***P,.001.
doi:10.1371/journal.pone.0108477.g004
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increased numbers of blood vessels in the muscular package at the
base of the peritoneal membrane as compared with the control
mice. The paricalcitol group had fewer blood vessels at the base
and no blood vessels embedded in the inflammatory zone
(Figure 1E).
Paricalcitol treatment increased T cell populations in the
peritoneal cavity
We next analyzed the phenotype of the leukocytes present
within the peritoneal cavity after treatment. The paricalcitol-
treated mice tended to have a higher number of nucleated cells
(Figure 2A); however, the number of B cells in the control group
was higher than in the PDF group and similar to that observed in
the paricalcitol group (Figure 2B). The PDF- and paricalcitol-
treated mice presented a higher number of total macrophages
(Figure 2C), and the number of B cells and macrophages were
similar between both groups (Figure 2B and 2C, respectively). The
PDF and paricalcitol groups had a higher number of T cells as
compared with the control group. However, the paricalcitol group
had increased numbers of CD4+ (Figure 2D) and CD8+
(Figure 2E) T cells as compared with the PDF group.
The numbers of CD4+ and CD8+ T cells in the mice exposed to
PDF and treated or not treated with paricalcitol were inversely
correlated with peritoneal membrane thickness (Figure 3). This
result strongly suggests that the effect of paricalcitol treatment on
T cells might play a role in the prevention of peritoneal fibrosis.
Paricalcitol increased the number of T cells expressing a
regulatory phenotype in the peritoneal cavity
Vitamin D has previously been associated with the activation
and proliferation of CD4+ T regulatory cells [18]. Regulatory T
cells are characterized by the expression of Forkhead P3 (Foxp3)
transcription factor and the membrane antigens cytotoxic T-
lymphocyte antigen-4 (CTLA-4) and TGF-b. These cells are
responsible for the regulation of the immune response. The
paricalcitol-treated mice tended to have higher frequency of Foxp-
3+CD4+ T cells than that observed in the PDF group. However,
the frequency of CD8+ T cells expressing Foxp-3 was significantly
higher in the paricalcitol-treated mice than in the PDF-treated
mice (Figure 4A). Both the paricalcitol and the PDF groups
expressed similar frequencies of CD4+ T cells expressing CTLA-4+
and membrane TGF-b (Figure 4B and 4C, respectively), whereas
both markers were expressed at higher levels in the CD8+ T cells
of the paricalcitol-treated mice than in those of the PDF group.
These results clearly show that paricalcitol preferentially improves
the frequency of CD8+ Treg in the peritoneal cavities of mice
exposed to PDF. Nonetheless, the absolute number of CD4+ and
CD8+ T regulatory cells (FoxP3+) were higher in animals treated
with paricalcitol (Figure 4D).
Paricalcitol treatment did not interfere with chemokine
production
The levels of RANTES, MIP-1a and MIP-1b (Figs. 5A–5C,
respectively) were similar in both the paricalcitol and the PDF
groups. The results suggest that paricalcitol treatment did not
interfere with chemokine production.
Paricalcitol treatment reduced IL-17 concentrations in
the peritoneal cavity
Due to the fact that cytokines play a role in inflammation and
that Tregs regulate their production, the concentration of several
cytokines in the peritoneal cavity was determined. The results
showed that paricalcitol did not significantly reduce the concen-
trations of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, TNF-a, IFN-c and
TGF-b compared with the PDF group (Figure 6A). However, the
PDF group presented significantly higher levels of IL-17 than the
paricalcitol group (P,.01) (Figure 6B). Furthermore, IL-17 levels
were strongly correlated with peritoneal thickness (Figure 6C),
suggesting that IL-17 plays an important role in the development
of peritoneal fibrosis and that the prevention of fibrosis by
paricalcitol might be directly linked to the downregulation of IL-
17 cytokine levels.
Peritoneal CD4+ and CD8+ T cells from the paricalcitol-
treated mice reduced the production of IL-17 production
by in vitro-stimulated T cells
Given that regulatory T cells could affect the production of IL-
17, we investigated if peritoneal CD4+ and CD8+ T cells from
mice treated or not with paricalcitol can regulate the production of
IL-17 by in vitro-stimulated CD4+ T cells. For this purpose, a cell
population enriched in CD4+ or CD8+ T cells from PDF- or
paricalcitol-treated mice was stained with PKH67 and cocultured
in the presence of peritoneal CD3+ T cells from mice treated with
PDF. The cultures were stimulated with anti-CD3 and anti-CD28
antibodies, and the frequency of CD4+IL-17+ T cells in the
PKH67 ———negative population was determined. The results in Figure 7
show that both peritoneal CD4+ and CD8+ T cells-enriched
populations from paricalcitol-treated mice reduced the frequency
of IL-17+CD4+ T cells obtained from the peritoneum of mice
treated only with PDF. This frequency was significantly lower than
that observed when analyzing CD4+ or CD8+ T cells-enriched
populations from PDF-treated mice.
Figure 5. Chemokine concentrations in the peritoneal cavity were not affected by paricalcitol treatment. Concentrations of RANTES (A),
MIP-1a (B) and MIP-1b (C) were determined in the peritoneal washing fluid. We observed no difference between the paricalcitol and the PDF group.
n$5 in each group.
doi:10.1371/journal.pone.0108477.g005
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Discussion
Fibrosis is the final consequence of a chronic inflammatory
reaction [19,20,21]. Therefore, regulation of the inflammatory
reaction could have beneficial effects on fibrotic disorders. VDR
signaling has previously been shown to regulate inflammation [18]
and has shown fibroprotective activity in various organs
[22,23,24]. Various mechanisms have been proposed to explain
the role of VDR signaling in fibrosis regulation, but it is still poorly
understood. The activation of this pathway has been shown to
inhibit myofibroblast activation [25], to induce differentiation of
mesenchymal precursors into a non-fibrogenic phenotype [26] and
to reduce inflammation through NF-kB sequestration [16]. These
mechanisms are not mutually exclusive and might work together.
Inflammation is a key event in wound healing and fibrosis [27].
It is known that macrophages play an important role in the fibrotic
process through the secretion of growth factors such as TGF-b and
FGF. Here we addressed the role of paricalcitol in the
development of fibrosis using a mouse model of peritoneal dialysis.
Given that inflammation plays an important role in fibrosis, we
centered our attention on the inflammatory mechanisms.
As previously reported by our group [8], peritoneal exposure to
PDF induced increased numbers of inflammatory cells at the
peritoneal cavity, composed primarily of macrophages. However,
the number of CD4+ and CD8+ T cells in the peritoneal cavity of
mice exposed to PDF increased as well. T cells are responsible for
the orchestration of inflammatory responses through the secretion
of cytokines, which also play a role in fibrosis by the activation of
fibroblasts [28,29] and fibrocytes [30]. Th2 responses are
associated with fibrosis development, whereas Th1 responses are
associated with anti-fibrotic actions [20,31]. However, Th1 type
responses have also been implicated in peritoneal fibrotic adhesion
[32] and autoimmune-induced cardiac fibrosis [33], whereas Th17
responses have been related to fibrosis in the kidneys [34], lung
[35] and skin [36]. We have recently demonstrated that IL-17
plays an important role in the generation of PDF-induced
peritoneal fibrosis in patients and mice exposed to PDF [37].
CD4+ T cells were the primary source of IL-17 in the peritoneum
of the mice treated with PDF. We have also demonstrated that the
direct administration of recombinant IL17 in the peritoneum
induced peritoneal fibrosis in mice [37]. These results reveal that,
depending on the model studied, different T cell phenotypes
appear to be potentially fibrogenic.
Several studies have assessed the cytokine pattern produced in
the peritoneal cavity of patients undergoing PD, with conflicting
results [38,39,40]. The discrepancy in these results could be
explained by the in vitro experimental approaches used. The PD
mouse model, contrary to expectations, revealed an upregulation
of all Th responses. This could be explained by the fact that
approaches using in vitro cell stimulation might induce biases in
cytokine production depending on the methodology used, whereas
for the PD mouse model, cytokines are produced in vivo in
response to PDF instillation.
Previous studies have demonstrated that VDR activation
induces an increased frequency of CD4+ regulatory T cells [18].
In this study, paricalcitol treatment tended to increase the
frequency of CD4+ T cells expressing Foxp3 (P= .054), whereas
the impact on the expression of other Treg markers was less
important. The treatment with paricalcitol, however, increased the
frequency of peritoneal CD8+ T cells expressing Foxp-3, CTLA-4
and membrane TGF-b. These results suggest that, at least in this
model, VDR signaling preferentially affects CD8+ T cells. This
selective effect on CD8+ T cells could be explained by the fact that
mature CD8+ T cells express higher concentrations of VDR than
CD4+ T cells [41]. To our knowledge, this was the first time that a
preferential effect on the activation/development of regulatory
CD8+ T cells was demonstrated in vivo.
As shown in Figure 3, the number of CD4+ and CD8+ T cells is
higher in paricalcitol-treated mice than in PDF mice. As a result of
the increased number of CD4+ T cells in paricalcitol and the
tendency towards and increased frequency of CD4+ T cells
expressing Foxp3, the number of peritoneal CD4+ Treg cells was
higher in paricalcitol than in PDF treated mice (P,.001).
Similarly, the number of peritoneal CD8+ T cells expressing
Foxp3 was higher in paricalcitol-treated than in PDF mice. This
outcome strongly suggests that the increased number of regulatory
T cells is responsible for inflammation regulation in the peritoneal
cavity.
The majority of studies concerning T cell-mediated regulation
of immune response have been focused on CD4+ T cells. The
existence of CD8+ T cells with regulatory activity (called
‘‘suppressor’’ cells) was demonstrated during the 1970s and
1980s, however, the study of these cells was hindered by technical
limitations. The interest in CD8+ regulatory T cells has recently
been revived, and increasing evidence points to their participation
in the control of various inflammatory processes [42] through the
regulation of IL-17 and IFN-c. The results presented here show
that paricalcitol treatment selectively reduced IL-17 peritoneal
Figure 6. Paricalcitol induced the regulation of IL-17 production and affected peritoneal fibrosis outcomes. A) Peritoneal
concentrations of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IFN-c and TNF-a were not affected by paricalcitol treatment. B) Paricalcitol induced the suppression
of IL-17 production in the peritoneal membrane. C) The IL-17 concentrations strongly correlate with peritoneal fibrosis. n$5 in each group. Statistical
significance was determined using the Mann-Whitney test. **P,.01. A correlation analysis was performed using Spearman’s nonparametric test.
doi:10.1371/journal.pone.0108477.g006
Figure 7. CD4+ and CD8+ T cells from paricalcitol-treated mice
regulate IL-17 production. CD4+- and CD8+-enriched T cell
populations from mice treated with PDF and paricalcitol were stained
with PKH67 and co-cultured with CD3+ T cells from PDF-treated mice. A
control group of CD3+ T enriched cells from PDF-treated mice was also
included. The cells were stimulated with CD3 and CD28, and after 2
days, brefeldin A was added for the last 12 h of culture. The cells were
stained with anti-CD4 and anti-IL-17 antibodies and analyzed by flow
cytometry. The PKH67negative CD4+ T cells were selected, and the
frequency of IL17+ cells is shown in the figure. Statistical significance
was determined using the Mann-Whitney test. **P,.01.
doi:10.1371/journal.pone.0108477.g007
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concentration. The regulation of IL-17 production was likely
mediated by both CD4+ and CD8+ T cells from paricalcitol-
treated mice. Although the frequencies of CD4+ T reg
(CD4+Foxp3+) from paricalcitol were no higher than in the PDF
group (P= .054), the absolute number of CD4+ Treg were
significantly increased and CD4+ T cells from paricalcitol-treated
mice appear to play a role in the prevention of PDF-induced
fibrosis (Figure 3). In addition, CD4+ T cells and CD8+ T cells
from the paricalcitol-treated mice, but not those from PDF mice,
were able to reduce the frequency of IL-17+ T cells in vitro
(Figure 7). This result clearly demonstrates that both, CD4+ and
CD8+ T cells are able to regulate IL-17 production in vitro. The
effect on IL-17 strongly correlated with decreased peritoneal
fibrosis [37]. However, given that regulatory T cells and IL-17-
secreting cells appear to have a common precursor, it does not
exclude the possibility that, in vivo, VDR signaling could stimulate
the differentiation into a regulatory T cell phenotype to the
detriment of the Th17+ T cells. We cannot rule out the possibility
that these mechanisms are working together.
VDR signaling has previously been related to fibroprotective
activity [25,26]. Various mechanisms have been proposed to
explain the role of VDR signaling in fibrosis regulation, but it is
still poorly understood. This study demonstrated that paricalcitol
administered intraperitoneally reduced peritoneal membrane
inflammation and fibrosis. The mechanism appears to be
dependent primarily on the activation of Treg cells and the
reduction of IL-17 secretion. These mechanisms are not mutually
exclusive and might work simultaneously.
VDR is also expressed in macrophages, which could play a role
in peritoneal fibrosis. Macrophages are the largest cell population
in the peritoneal cavity. VDR signaling promotes macrophage
differentiation into the M2 phenotype [43], which, as previously
demonstrated, is related to peritoneal fibrosis in PD-treated
patients [44]. In addition, the levels of TGF-b in the peritoneal
cavity of the mice treated with paricalcitol were no different than
those of the mice treated with PDF alone, and there was no
correlation with peritoneal fibrosis. It has been suggested that the
fibrotic activity of TGF-b is regulated by IL-17 and that
inflammation-induced fibrosis could be prevented by targeting
IL-17 [3434]. Therefore, at least in our model of PD-treated mice,
the evidence suggests that VDR signaling in macrophages might
not play a role in the prevention of peritoneal fibrosis.
Further studies will be required to elucidate other immunolog-
ical mechanisms involved in peritoneal fibrosis. However, the
results presented here strongly suggest that VDR signaling reduces
peritoneal fibrosis through the augment of the number Treg and
the downregulation of IL-17 production at peritoneum.
Conclusion
VDR signaling promotes the recruitment of CD4+ and CD8+ T
cells with regulatory activity into the peritoneal cavity, increasing
their number, reducing IL-17 production and diminishing PDF-
induced peritoneal inflammation and fibrosis. VDR signaling
could be used to reduce peritoneal fibrosis induced by chronic
exposure to PDF as well as surgery-induced adhesion.
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